MediciNova completes double-blind enrollment in Phase 2b/3 ALS trial; topline results expected end-2026
MediciNova announced completion of last patient, last visit in the double-blind portion of COMBAT-ALS, a 234-patient Phase 2b/3 trial of MN-166 (ibudilast) for ALS treatment. Topline results are expected by end-2026, with full study completion in March 2027.
How Oyticker scores a story: impact and confidence describe the information, not a probability that a price moves.
What happened
MediciNova completed enrollment and double-blind dosing in COMBAT-ALS on September 24, 2026. The trial randomized 234 participants across two arms at US and Canadian sites. Patients continue in open-label extension. Double-blind topline results are targeted for end-2026; final study completion (LPLV) is expected March 2027.
Why it matters
Completion of double-blind enrollment removes execution risk and moves the trial toward data readout. ALS is a high-unmet-need indication with limited approved therapies; positive efficacy or safety data could support regulatory approval and commercial opportunity. Timing of results (end-2026) is material for near-term catalyst and investor decision-making.
Market transmission
Positive topline results would support potential regulatory filing and approval pathway, expanding MediciNova's pipeline and revenue. Negative or inconclusive results would reduce asset value and increase discount rate applied to future cash flows. Results also inform risk premia for the stock and potential partnerships or licensing deals in neurodegenerative disease.
What to watch
Topline efficacy and safety data release (expected end-2026); regulatory feedback on filing strategy post-results; open-label extension safety and durability signals; competitive landscape for ALS therapeutics; any interim or subgroup analyses disclosed before full readout.
Source:GlobeNewswire US
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.